DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Current Location:
> This Story

starstarstarstarstar (1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Women's Health Homepage

American Society of Breast Surgeons proposes new screening guidelines ACR voices support for new approach, which is based on individual patient risk

Q&A with Danilo Gennari Discussing what DeHCA Light & Sound brings to breast cancer diagnoses

Latest ACP mammo guidelines elicit strong opposition Experts say findings could lead to 10,000 more breast cancer deaths annually

Study supports 3D mammography for older women, contrary to USPTSF recommendation New data sheds light on risk-benefit ratio of screening older patients

FDA proposes changes to mammography regulations First agency efforts to 'modernize' breast screening in over two decades

Not all breast density laws are created equally Research shows that the wording of some notifications result in supplemental testing, others don't

3D mammography helps avoid unnecessary breast biopsies, says study 33 percent difference in biopsy rate compared to standard mammography

New study finds AI breast screening interpretations on par with those of radiologists Could relieve high labor intensity of screening programs

South Dakota passes breast density law Will require all women who undergo mammograms to be notified of their breast density status

FDA warns against thermography alone for breast cancer detection Not a substitute for mammography

VolparaDensity scorecard

Volpara and GE expand breast density software partnership

by John R. Fischer , Staff Reporter
Volpara Solutions has expanded its existing relationship with GE Healthcare by making the tech giant the global distributor of its VolparaDensity software.

In use in more than 35 countries, VolparaDensity utilizes machine learning to analyze mammograms and provide automated, objective, and volumetric breast density assessments to help radiologists determine if patients require supplemental testing to confirm the presence of breast cancer. The expansion extends its use to GE customers outside of the U.S.

Story Continues Below Advertisement

RaySafe helps you avoid unnecessary radiation

RaySafe solutions are designed to minimize the need for user interaction, bringing unprecedented simplicity & usability to the X-ray room. We're committed to establishing a radiation safety culture wherever technicians & medical staff encounter radiation.

“Volpara Solutions and GE Healthcare have been partnering in the United States since 2015. Now GE customers outside of the United States can also purchase VolparaDensity bundled with GE's breast imaging modalities such as the Senographe Pristina and the Invenia Automated Breast Ultrasound (ABUS),” Dave Mezzoprete, director, business development of Volpara Solutions, told HCB News. “Volpara and GE can provide truly comprehensive dense breast screening.”

Around 40-50 percent of women in the U.S. possess dense breast tissue, a condition which raises the risk of developing breast cancer in one’s lifetime, and can obscure the presence of tumors and prevent them from being detected during routine 2D and 3D mammograms. Awareness of the risks of dense breast tissue is growing, as evidenced by the recent passage in the U.S. of a law requiring all mammography reports to include up-to-date information on the density of a patient’s breast tissue.

The use of advanced screening options, such as breast MR and breast ultrasound, including GE’s ABUS system, can more easily pick up on breast cancer, as evidenced, according to Mezzoprete, by the initial findings from a Dutch trial presented at ECR, which indicate a dramatic drop in the number of interval cancers for women with high volumetric breast density when subjected to these forms of imaging.

Designed to assign a breast density category in correlation with the fourth and fifth editions of the BI-RADS model, another study in 2018 found the clinical application to be on equal footing with the subjective evaluations of radiologists in accurately predicting a woman’s risk of developing breast cancer and the risk of interval cancers. Women with extremely dense breasts who were assessed with the system had a 5.65 times higher risk of interval cancer and a 1.43 times higher risk of screen-detected cancer than women with scattered fibroglandular densities.

The system is backed by more than 100 peer-reviewed papers in all, and more than 250 publications.

“The success and validation of VolparaDensity, with more than 100 peer-reviewed published papers, provides strong clinical support for dense breast screening and is an important driver of density awareness among clinicians,” said Mezzoprete. “When bundled together, VolparaDensity and the GE imaging modalities are ideal for dense breast screening. Facilities have access to a simple solution for ensuring that patients receive optimal screening when the sensitivity of mammography alone is too low.”

The system is FDA cleared and CE marked, and approved for use by Health Canada and Australia’s Therapeutic Goods Administration.

Women's Health Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2019, Inc.